BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24587142)

  • 1. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
    Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
    PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
    Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
    Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
    Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
    Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
    Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
    Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
    Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
    Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
    J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
    Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
    Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
    Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
    Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.
    Wu SG; Gow CH; Yu CJ; Chang YL; Yang CH; Hsu YC; Shih JY; Lee YC; Yang PC
    Eur Respir J; 2008 Oct; 32(4):924-30. PubMed ID: 18508816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD39 identifies a specific CD8 + T cell population in lung adenocarcinoma-related metastatic pleural effusion.
    Lv LL; Wang HB; Zhang YX; Zhai JW; Shen Y; Qu QX; Chen C
    BMC Immunol; 2023 Dec; 24(1):53. PubMed ID: 38087217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.